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Changes call for innovation, and innovation leads to progress

Li Keqiang
The revolution in biological discovery and previously unanticipated strides in technology are transforming patient management and healthcare delivery. 1 This transformation reflects the logarithmic growth in molecular innovation driven by public investment in creating platforms for healthcare solutions that benefit populations, now and for future generations. 2 This scientific evolution propels the development of precision solutions, exploiting insights in pathophysiology at the molecular level that provides mechanism-based targets for advanced therapies, amplifies the ability to affect cures, and eliminates adverse events. 3 Indeed, the growing toolbox of next-generation platforms has produced unprecedented opportunities to personalize pharmacological and technological therapies that can be positioned across the spectrum of diseases, populations, and geographies to reach the global community. 4 In turn, the emerging framework established by molecularly targeted diagnostic and therapeutic paradigms transforms the traditional one-size-fits-all approach to patient management into individualized healthcare solutions. 5 The profound impact of this scientific revolution on global health can best be appreciated by considering the overwhelming success of the output of therapeutic innovation in the biotechnology and biopharmaceutical sector recently highlighted in this journal. 6 Indeed, in the last 30 years, this "Bioinnovation Enterprise" has emerged as one of the largest growth sectors in drug development, with >200 therapies emerging for >250 indications from >4,000
biotechnology companies worldwide with a combined value of $185 billion. In 2012, biotechnology product sales worldwide were an estimated $163 billion, which constituted ~19% of the total prescription product sales. Of 119 overall products categorized as blockbusters (sales over $1 billion per year), 47 (39%) were biotechnology products. The prominence of this sector in therapeutic innovation is reflected by the fact that the overwhelming majority of new molecular entities approved by the FDA over the last 3 years, 4 and those predicted to transform the care of patients in their respective disease classes, are products of the evolving Bioinnovation Enterprise. 7, 8 Case in point, the impact of this innovation is highlighted by emerging paradigms for the management of asthma. 9 This disease currently afflicts 300 million people globally, a number which is expected to rise to 400 million by 2020. While most patients are satisfactorily controlled on established treatments, 5% remain poorly controlled. In that context, innovative treatments have the potential to provide options for these unfortunate patients. Moreover, the economic and healthcare benefits of treating poorly controlled asthma are substantial and in The Bioinnovation Enterprise is poised to transform the rapid pace of knowledge generation in pathobiology into therapeutic innovations for global populations. The impact of this transformation on the drug development and healthcare delivery landscapes will undoubtedly escalate over the coming years, driven by the dual engines of exponential
